On October 13th, Pembrolizumab (Keytruda; Merck, USA) was approved by the Food and Drug Administration in 2021 for the treatment of patients with metastatic, persistent, or recurrent cervical cancer whose tumors express PD-L1 (CPS ≥ 1). This evidence concerns the gene CD274 and cervical carcinoma.